All In Biotech

NDA 050734 · Pfizer

Idarubicin Hydrochloride

Idarubicin Hydrochloride · Intravenous

Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Feb 17, 1997

Approved uses

1

Original approval plus efficacy supplements

Registered trials

336

104 Phase 3, 55 recruiting

FAERS reports

1,159

1,145 serious, 253 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CARDIOMYOPATHY, SECONDARY MALIGNANCIES, and EXTRAVASATION AND TISSUE NECROSIS • Cardiomyopathy: IDAMYCIN PFS can cause myocardial damage, including acute left ventricular failure, during or after termination of therapy. The risk of cardiomyopathy is increased in patients who have received prior anthracyclines or who have pre-existing cardiac disease. Assess left ventricular cardiac function prior to initiation of IDAMYCIN PFS and during and after treatment [see Warnings and Precautions (5.1) ] . • Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including IDAMYCIN PFS [see Warnings and Precautions (5.2) ] . • Extravasation and Tissue Necrosis: Extravasation of IDAMYCIN PFS during administration can result in local tissue injury and necrosis. Immediately...

What it is approved for

From the label in effect Apr 15, 2026.

IDAMYCIN PFS is indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen. IDAMYCIN PFS is an anthracycline topoisomerase inhibitor indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen. (1)

Mechanism: Idarubicin hydrochloride has antimitotic and cytotoxic activity through forming complexes with the DNA, inhibiting nucleic acid synthesis, inhibiting topoisomerase II activity, and producing DNA-damaging free radicals.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 17, 1997 Original approval · Type 3 - New Dosage Form
3 products under this application
  • IDARUBICIN HYDROCHLORIDE · IDARUBICIN HYDROCHLORIDE 20MG/20ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • IDAMYCIN PFS · IDARUBICIN HYDROCHLORIDE 5MG/5ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • IDARUBICIN HYDROCHLORIDE · IDARUBICIN HYDROCHLORIDE 10MG/10ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Idarubicin" as an intervention, any sponsor and status, largest first.

All 336 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • myelosuppression195
  • febrile neutropenia152
  • pyrexia100
  • off label use66
  • white blood cell count decreased62
  • pneumonia61
  • platelet count decreased54
  • infection53
  • neutropenia51
  • neutrophil count decreased49
  • nausea46
  • death43

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20052
20062
20073
20082
20097
20108
201136
201227
201310
201416
201532
201616
201733
201860
201952
202046
202177
2022155
2023185
2024140
2025149
2026100

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 536 on PubMed

Sponsor: Pfizer · Also marketed as Idamycin Pfs

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.